Quantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™

Rhea-AI Summary

Quantum-Si (Nasdaq: QSI) has begun shipping its latest benchtop protein sequencer, Platinum® Pro, designed to make Next-Gen Protein Sequencing™ more accessible globally. The new system builds upon the original Platinum model with enhanced features including:

• An enlarged touchscreen with intuitive user interface
• Flexible local or cloud-based data analysis options
• Pro Mode for custom application development through a Technology Access Program

The system offers single-molecule precision protein analysis through an integrated workflow and is now available in over 30 countries through direct and channel partner networks. According to CEO Jeff Hawkins, Platinum Pro aims to advance proteomics research and enable new biomarker discoveries.

Positive

• Commercial launch of new product Platinum Pro initiated with shipments beginning
• Expanded market reach with availability in over 30 countries
• Enhanced features and capabilities compared to previous model

Negative

• None.

Insights

Life Sciences Technology Expert

Quantum-Si's announcement of Platinum Pro shipments marks a significant commercial execution milestone in the protein sequencing market. The upgraded instrument builds upon their first-generation technology with practical enhancements that address key user experience barriers in complex proteomics workflows.

The technical improvements focus on usability and flexibility rather than just raw performance, suggesting QSI is maturing its approach to the market. The expanded touchscreen interface targets a pain point in laboratory instruments where complex workflows often require specialized training. Meanwhile, the dual-analysis pathway (local/cloud) shows awareness of varying IT infrastructure and data security requirements across research settings.

Most notably, the Pro Mode feature with Technology Access Program signals QSI's strategic shift toward collaborative application development with biopharmaceutical partners. This approach recognizes that technology adoption in proteomics often depends on proven, specific use cases rather than general capabilities.

The 30-country availability is particularly impressive for a specialized instrument company of QSI's size, suggesting they've successfully established distribution partnerships to scale their commercial reach without building extensive direct sales forces in each market. This balanced approach to commercialization helps manage cash burn while expanding market presence.

Financial Analyst

This product shipment announcement represents a positive commercial progression for Quantum-Si as the company transitions from pure R&D into revenue-generating operations. For biotech tools companies, successful commercialization of next-generation platforms is a fundamental value-creation milestone that typically precedes revenue acceleration.

The expanded feature set of Platinum Pro suggests QSI has incorporated early customer feedback from its original platform, which typically improves product-market fit and can accelerate adoption rates. The Technology Access Program structure for Pro Mode is particularly shrewd from a financial perspective - it creates a pathway for partnership revenue and application co-development while controlling support costs.

With a current market capitalization of approximately $273 million and modest stock price of $1.41, QSI remains in the early commercialization phase where execution on product launches significantly impacts investor confidence. The multi-country distribution announced suggests efficient use of channel partnerships to maximize market coverage while managing operating expenses.

While the announcement lacks specific revenue projections or pricing details, the transition to shipping product represents a crucial inflection point that differentiates QSI from pre-commercial proteomics technology companies. Investors should monitor upcoming quarters for initial revenue contribution and customer adoption metrics which will ultimately determine the financial impact of this product launch.

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company^™, announces the start of shipments for its latest benchtop sequencer, Platinum^® Pro. This groundbreaking instrument offers protein analysis with single-molecule precision, aiming to make Next-Gen Protein Sequencing™ more accessible to laboratories worldwide.

Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins through a simple, integrated workflow. Building upon the foundation of innovation established by the original Platinum, the new system introduces advanced features tailored to the evolving needs of researchers and biopharmaceutical customers. Key innovations include:

• Streamlined User Experience: An enlarged touchscreen with an intuitive user interface guides users through each run, supporting diverse applications from proteoform analysis to protein barcoding.
• Flexible Data Analysis: Options for local or cloud-based data analysis provide versatility to suit various research environments.
• Pro Mode: This feature empowers custom application development, offered through a Technology Access Program, positioning Platinum Pro as a platform for biopharmaceutical innovation and application co-development.

"We are committed to delivering tools that advance proteomics research," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "The introduction of Platinum Pro provides researchers with additional features and capabilities to enable insights which we believe will positively impact scientific research and lead to the discoveries of new biomarkers in the future.”

Platinum Pro exemplifies Quantum-Si’s dedication to progressive innovation that delivers solutions for Next-Gen Protein Sequencing. With its robust capabilities, the system is expected to drive new opportunities for breakthrough discoveries. Platinum Pro shipments have started, and the system is available in more than 30 countries through Quantum-Si’s direct and channel partner network, marking a significant milestone in making advanced proteomics tools more accessible to every lab, everywhere.

For more information or to place an order, visit: Quantum-Si

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum^® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2025. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instruments and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250326161988/en/

Investor Contact

Jeff Keyes

Chief Financial Officer

ir@quantum-si.com

Media Contact

Katherine Atkinson

SVP, Commercial Marketing

media@quantum-si.com

Source: Quantum-Si Incorporated

FAQ

What new features does Quantum-Si's Platinum Pro (QSI) offer compared to the original Platinum?

Platinum Pro introduces an enlarged touchscreen interface, flexible local/cloud data analysis options, and a Pro Mode for custom application development through a Technology Access Program.

How widely available is the Quantum-Si (QSI) Platinum Pro protein sequencer?

The Platinum Pro is available in more than 30 countries through Quantum-Si's direct and channel partner network.

What is the main purpose of Quantum-Si's (QSI) Platinum Pro system?

Platinum Pro offers protein analysis with single-molecule precision, making Next-Gen Protein Sequencing more accessible to laboratories worldwide.

What applications does the Quantum-Si (QSI) Platinum Pro support?

The system supports diverse applications including proteoform analysis and protein barcoding through an integrated workflow.